WashU Sonographer helps save a life with CPR

WashU Sonographer helps save a life with CPR
Megan Hangyal, an ultrasound sonographer who works at the Center for Advanced Medicine in South County, was celebrating with family and friends at Arnold Days when the crowd around her began to panic. As some fellow attendees asked if medical professionals were present, Megan snapped into action.

CDL Echo Capacity and Workflow Optimization project wins 2025 QUEST award

CDL Echo Capacity and Workflow Optimization project wins 2025 QUEST award
The team in the Cardiac Diagnostic Lab, located on the Barnes-Jewish campus, have won a 2025 QUEST (Quality, Excellence and Safety Team) award. This BJH award recognizes contributions made to improve organization performance and quality of care through the use of process and outcome measures. The CDL submission, CDL Echo Capacity and Workflow Optimization, also reflected goals of the BJC Heart & Vascular Growth Initiative.

Meet the pioneers of Heart and Vascular care (Links to an external site)

Meet the pioneers of Heart and Vascular care
From the earliest understanding of the body’s circulatory system to today’s groundbreaking treatments, the practice of heart and vascular medicine has continuously evolved in the search for new and better ways to protect and preserve the heart’s essential functions. Specialists at the Washington University and Barnes-Jewish Heart & Vascular Center are at the vanguard of this evolution, discovering new treatments and advancing compassionate care.

Immunotherapy may treat heart failure from ‘red devil chemo’

Immunotherapy may treat heart failure from ‘red devil chemo’
Doxorubicin has been a mainstay in cancer treatment for more than 50 years. Sometimes called “red devil chemo,” it is potent and effective against many cancer types. But it comes with a major downside — increased risk of severe heart failure, even decades after successful cancer treatment.Now researchers led by WashU Medicine cardiologist Ali Javaheri, MD, PhD, have identified a type of immunotherapy that prevents and treats the heart muscle damage caused by doxorubicin, based on their findings in human heart tissue, cell lines and mouse models of heart failure. The study appears in the journal Circulation.

Barriers Remain to Widespread Use of Polypills for CVD Therapy in High-Income Nations As Testing Continues (Links to an external site)

Barriers Remain to Widespread Use of Polypills for CVD Therapy in High-Income Nations As Testing Continues
“These medications are saving lives,” said Anubha Agarwal, MD, assistant professor of medicine of cardiology and co-director of the program in global cardiovascular health at WashU Medicine in St. Louis. “There is not a financial incentive to produce them, which is an issue in high-income countries like the US and the UK.”